Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 368

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists

Open access
Toy, Weiyi, Weir, Hazel, Razavi, Pedram, Lawson, Mandy, Goeppert, Anne U., Mazzola, Anne Marie, Smith, Aaron, Wilson, Joanne, Morrow, Christopher, Wong, Wai Lin, De Stanchina, Elisa, Carlson, Kathryn E., Martin, Teresa S., Uddin, Sharmeen, Li, Zhiqiang, Fanning, Sean, Katzenellenbogen, John A., Greene, Geoffrey, Baselga, José, Chandarlapaty, Sarat·2017·Cancer Discovery

Abstract

Recent studies have identified somatic ESR1 mutations in patients with metastatic breast cancer and found some of them to promote estrogen-independent activation of the receptor. The degree to which all recurrent mutants can drive estrogen-independent activities and reduced sensitivity to ER antagonists like fulvestrant is not established. In this report, we characterize the spectrum of ESR1 mutations from more than 900 patients. ESR1 mutations were detected in 10%, with D538G being the most frequent (36%), followed by Y537S (14%). Several novel, activating mutations were also detected (e.g., L469V, V422del, and Y537D). Although many mutations lead to constitutive activity and reduced sensitivity to ER antagonists, only select mutants such as Y537S caused a magnitude of change associated with fulvestrant resistance in vivo. Correspondingly, tumors driven by Y537S, but not D5358G, E380Q, or S463P, were less effectively inhibited by fulvestrant than more potent and bioavailable antagonists, including AZD9496. These data point to a need for antagonists with optimal pharmacokinetic properties to realize clinical efficacy against certain ESR1 mutants. Significance: A diversity of activating ESR1 mutations exist, only some of which confer resistance to existing ER antagonists that might be overcome by next-generation inhibitors such as AZD9496. Cancer Discov; 7(3); 277–87. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 235

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-1523

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 368

Metadata

Authors
Toy, W., Weir, H., Razavi, P., Lawson, M., Goeppert, A. U., Mazzola, A. M., Smith, A., Wilson, J., Morrow, C., Wong, W. L., De Stanchina, E., Carlson, K. E., Martin, T. S., Uddin, S., Li, Z., Fanning, S., Katzenellenbogen, J. A., Greene, G., Baselga, J., & Chandarlapaty, S.
Venue
Cancer Discovery
Published
2017-03-01
Volume
7
Issue
3
Pages
277-287
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2565707423
Cited by
368
References
27
FWCI
21.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. https://app.cochat.ai/papers/10.1158/2159-8290.cd-15-1523
The paper
Toy, W., Weir, H., Razavi, P., Lawson, M., Goeppert, A. U., Mazzola, A. M., Smith, A., Wilson, J., Morrow, C., Wong, W. L., De Stanchina, E., Carlson, K. E., Martin, T. S., Uddin, S., Li, Z., Fanning, S., Katzenellenbogen, J. A., Greene, G., Baselga, J., & Chandarlapaty, S. (2017). Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-15-1523

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.